The former head of the FDA on Tuesday criticized the Trump administration’s efforts to lay off recently hired employees who review the safety of medical devices and other products.

The federal government said it 'ran afoul of no statute' when it announced a 15% cap on indirect cost reimbursements for NIH ...

A judge in Singapore ordered the freezing of KBP Biosciences’ assets while Novo Nordisk pursues $830 million in damages over claims that it was deceived in a 2023 licensing deal.

Siegfried’s stock dipped by 6% on the Swiss stock exchange Tuesday after reporting a lower-than-expected sales forecast for ...

Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move ...

Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...

A month af­ter Bio­gen sig­naled plans to shift its at­ten­tion to “ ex­ter­nal op­por­tu­ni­ties ,” it de­liv­ered on that ...

Subsense, a startup building noninvasive technology to communicate with the brain, is launching with $17 million in funding.

AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemotherapy-induced pain due to a ...

A biotech based in Vilnius, Lithuania has won the backing of Lux Capital as the startup plots a US expansion in 2025. Lux led ...

FDA approves Ono Pharmaceutical's Romvimza for TGCT, meaning it will compete with Daiichi Sankyo's Turalio. Drug shows better safety profile and twice-weekly dosing vs twice-daily Turalio.

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug ...